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ABSTRACT 
Objective: The main purpose of this study was to formulate and statistically evaluate 300 mg floating tablets of valsartan.  
Methods: Floating tablets of valsartan was prepared in 16 station rotary punching machine by considering 300 mg of valsartan as drug, 40-60 mg of 
hydroxypropyl methylcellulose (HPMC) K100M and 20-40 mg of poly (styrene-divinylbenzene) as polymers and 20 mg of sodium bicarbonate as 
gas generating agents. Since upper stomach has maximum therapeutic window for valsartan absorption, hence Gastroretentive Floating Tablets 
(GRFTs) was prepared by implementing Box-Bentham Design. The pre and post compression parameters were optimized using Statistica 10 
software. From the in vitro buoyancy and drug release studies and interpretation of statistical outcomes viz. Akaike Information Criterion (AIC), 
Bayesian Information Criterion (BIC), Root Mean Squared Error (RMSE), Dissolution Efficiency (DE), Mean Dissolution Time (MDT), desirability 
study, it was concluded that batch VF5 formulation was found to be the most optimized formulation.  
Results: The floating time of VF5 was found to be 132±0.33 sec, in vitro buoyancy time was 18 h, Akaike Information Criterion (AIC) was 54.97, 
Bayesian Information Criterion (BIC) was 5.13, percentage dissolution efficacy was 56.39%, mean dissolution time was 5.19hr. Further, six-month 
stability study was performed as per ICH QIA guideline. After performing two-way ANOVA within stability study response variables, it was 
confirmed that the interaction was most significant.  
Conclusion: Valsartan floating drug delivery system was successfully developed by considering HPMC K100M and poly (styrene-divinylbenzene) as 
polymers. Among all the nine batches, VF5 was found to be the best-optimized batch.  
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INTRODUCTION 
Valsartan is basically an angiotensin II receptor antagonist. It has partial 
affinity for type I angiotensin receptor. Valsartan helps to reduce the 
blood pressure by blocking the action of angiotensin, which tenses to 
dilate blood vessels. It has versatile use in the treatment of Congestive 
Heart Failure (CHF), Post-Myocardial Infraction (MI). Eventually, 
valsartan blocks the binding of angiotensin II to the ATI receptor in 
adrenal gland and vascular smooth muscle [1]. Valsartan also restrict 
aldosterone secreting effects of angiotensin II, which ultimately leads to 
vasoconstriction [2]. The Biopharmaceutics Classification System (BCS) 
class II drug valsartan, is a white to partially fine powder with a 
molecular weight of 435.5 Daltons. Valsartan is slightly soluble in water 
but has good solubility in methanol and ethanol. The dose of valsartan is 
40 mg, 80 mg, and 320 mg. The LogP value of valsartan is 5.8 with 7.5hr 
of plasma half-life during oral administration [3]. Valsartan has higher 
therapeutic window at upper stomach. To target the upper stomach, 
Gastro Retentive Drug Delivery System (GRDDS) is one of the best 
approaches for valsartan drug delivery [4]. Hence, valsartan floating 
drug delivery system was planned, considering hydroxypropyl 
methylcellulose (HPMC) K100M and poly (styrene-divinylbenzene) as 
polymer. Valsartan has only 3% oral bioavailability, which means 
improvement of its bioavailability by sustaining its duration of drug 
release could be a novel approach [5]. In floating drug delivery system, 
the formulation retains in upper stomach for prolong period of time as 
this system has lower density then the Gastrointestinal Tract (GIT) fluid 
[6]. But most importantly, statistical interpretation of evaluation 
variables and optimization using Box-Bentham design could make this 
research more reliable[5]. Therefore, the basic interest of this research 
was to establish a proper statistical model and based on that optimizing 
best formulation.  
MATERIALS AND METHODS 
The drug valsartan was purchased from Pro Lab Marketing Pvt. Ltd. 
New Delhi, HPMC K100M was purchased from Kalpana Polymers 
Private Limited, Mumbai-India, poly (styrene-divinylbenzene) was 
purchased from Rishichem Distributors Private Limited, Mumbai-
India. Lactose, sodium citrate, dicalcium phosphate, magnesium 
stearate, talc was gifted from Balaji Chemicals Vapi, Gujarat, India. 
All the other chemicals are reagents used were of pharmaceutical 
and analytical grads. For better results double distilled water was 
used throughout the experiment.  
Drug excipient compatibility studies using FTIR and DSC  
The pure drug valsartan was mixed with various polymers like 
HPMC K100M and poly (styrene-divinylbenzene). Further, IR 
mixture of all the components was prepared by considering 
potassium bromide (KBr); as an alkali halide which helps to form a 
sheet that is transparent in the infrared region during pellet formation 
[7]. The pellet was formed by applying 10 tons of pressure in hydraulic 
press. The prepared pellets were scanned at 400 to 4000 cm-1 
wavenumber range in Fourier-Transform Infrared Spectroscopy (FTIR) 
Model ALPHAT, Libindia Analytical Instrument. Same way possibilities of 
drug excipient compatibility were identified by Differential Scanning 
Calorimetry (DSC). The changes of melting endotherms or variations of 
corresponding enthalpy of reactions helps to identify possible drug 
excipient interactions. In this experiment, DSC thermographs of pure 
valsartan drug, a mixture of drug with HPMC K100M and poly (styrene-
divinylbenzene) were recorded. Using aluminum cells, the samples were 
separately sealed and analysed using DSC-60 instrument (Shimadzu 
Corporation, Tokyo, Japan). During this experiment temperature range 
were set up to 50-200 °C. The experiment was carried out in a nitrogen 
atmosphere at a heating rate of 5 °C/minute.  
Implementation of box-bentham design 
When the variables and results of experiment having non-linear 
relationship, then Box-Bentham design could be the best alternative. 
With this design, nonlinear quadric effect and interaction between two 
variables can be studied [8]. In this experiment, the joint influence of 
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independent variables concentration of HPMC K100M [X1] and poly 
(styrene-divinylbenzene) [X2] on the dependent variables, i.e. % 
Cumulative Drug Release (CDR) at 4th hour(Y1) and % CDR at 8th hour 
(Y2). In this design two factors were investigated each at three levels. The 
possible experimental trials were considered up to nine batches (table 1-
2). The further polynomial equation was established. The full model 
polynomial equation was established for this design. 
Y=β0+β1X1+β2X2+β12X1X2+β11X12+β22X22+E, 
Where, β0 is intercepted, which is constant. The β1 and β2 are 
coefficient of X1 and X2, β12 is the coefficient of interaction between X1 
X2. The response variables mean Y1 and Y2 are subjected to multiple 
linear regression analysis. A further amount of formulation variables 
was optimized [9].  
Preparation of valsartan floating matrix tablet 
At first, the required quantities of drug, polymer, and excipients were 
accurately weighed and passed through sieve number 80 for proper size 
separation [10]. Further, along with valsartan, principal polymer HPMC 
K100M and low-density copolymer poly (styrene-divinylbenzene) were 
mixed geometrically. The effervescent agent i.e. Sodium bicarbonate, 
glidant i. e talc and magnesium stearate were added further in the 
polymeric drug mixture. These powder mixtures were than bladed using 
1L Laboratory Blender (Thomas Scientific) and sieved using #40 mesh. 
This blend was compressed using 12 mm diameter flat punch. For 
punching purposes, 16 stations rotary punching machine (Pacific tool 
private limited) was utilized. For this operation, type B tooling tablet 
punch was functionalized with 133.6 mm punch length and 19 mm 
punch diameter. The die diameter was 30.15 mm and die height was 
2.22 mm. The operational tablets were in plane face with 16±1.25 mm 
tablet size. The hardness of the operational twenty tablets was found on 
an average between 4-7 kg/cm2.  
Evaluation parameters for valsartan floating tablet 
Precompression parameters 
Bulk density (BD) 
Accurately 10 gm of excipients containing valsartan mixtures were 
taken and passed through sieve number #10 and transferred into 
100 ml polypropylene-based graduated cylinder (Karter Scientific 
19H2). Without any further compaction, settle the powder within 
and read the total volume it occupied. Then calculate the apparent 
bulk density (g/cm3) using following formula:  
Bulk density= Total weight of granules 
Bulk volume 
 
Tapped density (TD) 
The powder mixture containing valsartan, which was in the 100 ml 
graduated cylinder was further compact using 50 ml capacities 
digital tapped density apparatus (DBK Instruments Jogeshwari East, 
Mumbai), which could provide flexible drops of 14±2 mm at a 
marginal rate of 300 drops per minute. Initially, the cylinder was 
tapped for 500 times and tapped volume was been measured (V1). 
Further, more 750 times tapping were recorded. The tapped volume 
was considered as V2. As per procedure if the difference between V1 
and V2 is lesser then %, then the final volume (V2) can be considered 
for final tapped volume. The calculative tapped density (g/cm3) was 
measured by following formula:  
Tapped density=Weight of the granuls 
Final tapped volume 
 
Hausner ratio 
This is basically a fractional number which helps to predict flowability 
of powders or granules. If the Hausner ratio of any granules or 
powders is more than 1.25, which indicates poor flowability. Hausner 
Ratio can be represented by the following equation:  
Hausner Ratio=Tapped Density 
Bulk Density 
 
Carr’s index 
The particular compressibility and cohesivity of granules can be 
measured by Carr’s index or Carr’s compressibility index. This is also 
an important parameter to measure the particle size of granules. If 
Carr’s Index of any granules is between 5-15%, indicates that the 
granules have excellent flowability. 
Carr’s Index=Tapped density−Bulk dennsity 
Tapped density 
×100 
Angle of repose 
Using the funnel method, the angle of repose of powder was 
determined. The funnel was filed with accurately weighted granules. 
The height of the funnel was adjusted such a way that, the funnel tip 
can touch apex of the powder blend. The final bland of granules were 
allowed to flow through the funnel tip into the surface of graph 
paper. The diameter of powder cone was measured and angle repose 
was calculated using following formula. 
Ө = tan-1 h/r 
Total porosity  
At first total volume of granules occupied in 100 ml cylinder was 
measured, then tapped volume was noted down after 100 tapping. 
The volume of the void was calculated as the difference between 
total volume of granules and tapped volume. The percentage 
porosity was calculated using the following formula:  
Porosity = (Total Volume-Volume of the Solid)/Total Volume) x 100%.  
Drug content 
An accurately weight of 100 mg of valsartan powder blend. This 
blend was further extracted with 0.1 N HCl and the solution was 
filter through 0.45µ membrane. The absorbance was measured at 50 
nm after suitable dilution using Shimadzu UV-1601PC UV-Visible, 
Scanning Spectrophotometer.  
Post compression parameters 
Weight variation 
Randomly twenty tablets were selected during process of 
manufacturing and average weight was measured. The individual 
tablet weight was measured and compared with average weight of 
tablets. The weight variation of tablet was estimated and percentage 
deviation was reported. Weight variation of all the batches of 
formulations was determined and recorded.  
Percentage deviation= Individual weight−Average weight 
Individual weight 
 
Hardness 
The hardness of the tablet was determined by Vin Syst Manual 
Tablet Hardness Tester (Monsanto Type); Model Number: VMT–1. 
Randomly three tablets from each batch were selected and the 
average hardness with standard deviation was recorded.  
Friability 
Friability test for uncoated tablets is prerequisite to know the 
tendency of tablets to chip, crumble or break during shipping, 
handling or during storage. Friability test was performed by HMK 
Tablet 1601 friabilator. Where, rotation speed was maintained 
around 5±1 revolution/minute, timings at 9:59:59 min. During drum 
rotation, ten pre-weighted tablets were subjected to fall within six 
inches of rotatory drum surface. After rotation cycle, tablets were 
dusted and once again weight was measured.  
Friability=Ten tablets weight before frability−Ten tablets weight after friability 
Ten tablets weight before friability 
×100 
Drug content 
At first, ten tablets were taken and the average weight was 
measured. Further, tablets were triturated to get fine powder. A 
certain quantity of powder equivalent to 80 mg of valsartan was 
taken and admixed with 100 ml of 0.1N HCL. The solution was 
further filtered using cellulose acetate membrane filter (0.30 µm). 
Further, 1 ml of this solution was diluted with 100 ml of 0.1N HCL 
and using Shimadzu UV-2600 spectrophotometer at 50 nm 
absorbance was taken to measure drug content.  
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In vitro buoyancy study 
The time at which tablet rises to the surface of dissolution medium is 
considered as floating time and the duration on which tablet floated 
on the dissolution medium was noted as floating lag time 
respectively. The test was performed at 37±0.5 °C in 50 ml beaker 
containing 00 ml of 0.1N HCL solution [11].  
In vitro drug release study 
Drug release study was attained by TDT-06P (Electrolab) USP type II 
dissolution testing apparatus. In this in vitro drug release study, 900 ml 
of 0.1N HCL were used as a dissolution media. The paddle RPM was set 
to 50 and the temperature was maintained around 37 °C±0.5 °C. During 
dissolution study at various time intervals, 5 ml of dissolution media was 
withdrawn and filtered using 0.45µ membrane filter. Simultaneously 
fresh 5 ml of 0.1N HCL was added in dissolution media to maintain 900 
ml of system volume. The samples were withdrawing for each one-hour 
interval and up to 8th hour samples were withdrawn. Freshly 
withdrawn samples were further diluted with 0.1N HCL and absorbance 
was taken at 50 nm using Shimadzu UV-1601PC UV-Visible, scanning 
spectrophotometer [12]. The amount of drug release was calculated 
using standard curve equation.  
Statistical analysis 
The statistical analysis of the variables is very essential to established 
good correlation between dependent and independent variables. The 
Box-Bentham design was established using Design Expert 11 (STATE-
EASE) and Minitab® 18 softwares. In this experiment, two factors that 
is % CDR at 2nd hour and % CDR at 8th hour have been evaluated, 
considering each at three levels (-1, 0,+1). Total nine batches of 
possible combinations were generated by Design of Expert 11 
software. Further, two-way analysis of variance was established. With 
this statistical model various graphical representations were also 
established to analysis each factor with different level of responses. 
The various graphical representations like, FDS graphs, Residual vs 
Predicted, Residual vs Actual, Counterplot of % CDR at 2nd and 8th hour 
respectively, 3D surface plot of % CDR at 2nd and 8th hour respectively, 
desirability, overlay plot, pareto chart of the standard effects, 
individual value analysis, probability plot, overlay plots were helps to 
analysis statistical models completely.  
Checkpoint batch and optimization of formulations  
The checkpoint batch was mandatory to find correlation between 
the polynomial equations and counterplot while predicting the 
responses. Optimization of the variables was measured using 
significant coefficients and R2 value.  
Kinetic studies 
Drug release studies can be well defined by selecting suitable kinetic 
models like zero order kinetics, first-order kinetics, higuchi model, 
hixson crowell cube root model, korsmeyer peppas equation [13]. 
Nevertheless, Akaike Information Criterion (AIC) [14], Bayesian 
Information Criterion (BIC) or Schwarz Criterion (SC), K1, Root Mean 
Squared Error (RMSC), Dissolution Efficiency (DE), Mean Dissolution 
Time (MDT) estimation using KinetDS 3 rev 010 software, helps to 
estimate the best fit model and best formulation within nine 
formulations [15].  
Stability study 
Accelerated stability studies was performed as per ICH guideline at 40 
°C± °C/75% RH±5% RH for 6 mo. Accelerated stability study on 
optimized formulations helps us to find the effect of ingredients on 
physical and chemical stability of active pharmaceutical ingredient of 
the dosage form. Tablet was stored in an aluminum foil and 
formulation was exposed in elevated temperature and humid 
conductions as specified earlier. Samples were withdrawn in every 
mounts and various evaluation tests were performed [12].  
RESULTS AND DISCUSSION  
IR and DSC results for valsartan and excipient compatibility 
It was observed that there was no chemical interaction between 
Valsartan and the polymers used. The functional group present in 
drug give peaks to specify the presence of 5-cyclic ring with oxygen 
atom, diamine and alkene, and other peaks for nitro groups. On the 
basis of DSC analysis, the valsartan melting point was found to be 
102.12 °C; however the melting isotherm shafted to 198.56 °C while 
combination with drug and polymers. 
Pre compression parameters and evaluations 
Each batch was planned for 50 tablets, hence 15g bland was 
prepared. Bulk density was measured using Veego digital bulk 
density apparatus (Model number: VTAP/MATIC-II). Bland was 
placed in 100 ml of polypropylene-based graduated cylinder (Karter 
Scientific 19H2) and bulk density was measured. Further using 100 
tapping of cylinder, tapped density was recorded. The various pre-
compression parameters were evaluated and were found to be 
within the prescribed limits. Using Statistica10® software, the pre 
compression parameters were recorded and variable importance 
graph was plotted. It was observed that total percentage porosity 
(power value: 0.996230) has maximum influence on floating tablet 
manufacturing and angle of repose (power value: 0.535868) has less 
importance on tablet preparation. All these results indicate, all the 
batches blend has well to passable flow and micropolitics (table 3-
4). In post-compression parameters at first, weight variations of 
tablets from the different batches was calculated and reported (table 
5). Almost all the formulation passed the weight variation test as the 
percentage weight variation was within the pharmacopeia limits 
of±5% of the weight. The VF3 formulation possessed maximum 
average weight of 302.21 mg with a weight variation of±0.514%, and 
the VF2 batch has less average weight of 98.23 mg with a weight 
variation of±0.809%. Similarly, the average drug content of VF6 
batch tablets was considered to be the highest i.e. 99.13%, where 
else VF1 shows less drug content of 92.24%. Further the hardness of 
all the batch samples was measured using tablet hardness tester 
(Monsanto Type); model number: VMT-1. The average hardness of 
VF8 batch was found to be maximum i.e. 6.4±0.27 kg/cm2 and VF5 
batch recorded lowest average hardness i.e. 4.8±0.51 kg/cm2. The 
average thickness of all the tablets was recorded using vernier 
calliper, VF6 batch recorded 5.1±0.15 mm thickness; which was 
considered to be minimum among all the batches, where else VF7 
recorded maximum thickness, which was recorded around 5.8±1.82 
mm. As far as the percentage friability was concerned, friability was 
recorded using HMK Tablet 1601 friabilator, considering 10 tablets 
of one batch at a time in friabilator. All the batches were recorded 
within the limit of friability range, however VF5 recorded maximum 
friability of 0.613±0.22%, where else VF1 shows lest friability of 
0.412±0.28% among all the batches. The floating time was a 
prerequisite variable for this formulation design. Floating time of 
VF1 was recorded 116±0.37see which is lest among of all the 
batches, where else VF3 shows maximum floating time of around 
136±0.02see. The formulation BF4, VF6 and VF9 shows maximum 
buoyancy where else VF1 shows minimum buoyancy within all the 
batches. Using Statistica10® software the post-compression 
parameters were recorded and variable importance graph was 
plotted. It was observed that average thickness (power value: 
0.923526) has maximum influence on floating tablet manufacturing 
and (power value: 0.535868) has less importance on tablet 
preparation. All these results indicate, all the batches blend has well 
to passable flow and micropolitics properties (table 6).  
In-vito drug release study 
All the nine batches (VF1-VF9) of valsartan floating tablets were 
developed considering HPMCK100M (40-60 mg) and poly (styrene-
divinylbenzene); 0-40 mg as polymers. All the batches were 
subjected to in vitro drug release study using 0.1N HCL for 12 h. The 
cumulative drug release profile was mentioned (fig. 1). The result 
shows that, VF5 formulation has controlled and better drug release 
profile (99.38±0.145 at 12th hours of dissolution) with 50 mg 
HPMCK100M and 30 mg poly (styrene-divinylbenzene) polymer 
concentration. There for it can be considered as optimum batch, 
however, proper statistical analysis and kinetic analysis was 
warranted to come in a conclusion.  
Statistical analysis 
Box-Bentham design was implemented to identified best possible 
factors. Preliminary investigation revealed that factor concentration of 
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poly (styrene-divinylbenzene) (20-40 mg)-X2 and HPMCK100M (40-60 
mg)-X1 is highly influenced the in vitro drug dissolution profile.  
Effect of polymers concentration on %CDR at 2nd h 
Using Design Expert® 11 software in vitro percentage cumulative 
drug release study was statistically interpreted at 2nd hour. Based on 
ANOVA analysis, quadric model was selected. In quadric model, F-
value was 1201.78, which implies the model was significant. There is 
only a 0.01% chance that an F-value this large could occur due to 
noise. Statistically, F value helps to indicate a group of variables are 
jointly significant or not. The F value of test is larger than F statistics, 
hence rejection of null hypothesis is palpable and accepting the 
alternative hypothesis was acceptable. Nevertheless, P-values less 
than 0.0500 indicate model terms were significant. In this case X1 X2, 
X1X2, X2² are significant model terms. Values greater than 0.1000 
indicate the model terms were not significant. The Predicted Quadric 
R² of 0.9944 is in reasonable agreement with the Adjusted R² of 
0.9987; i.e. the difference is less than 0.2 The Predicted R² of 0.9944 
is in reasonable agreement with the Adjusted R² of 0.9987; i.e. the 
difference is less than 0.2. Precision measures the signal to noise 
ratio. A ratio greater than 4 is desirable. In this experiment adequate 
precision was 102.608, indicates an adequate signal. This model can 
be used to navigate the design space. 
The polynomial equation for % CDR at 2nd Hour (Y1) =+28.39-
6.32X1-4.40X2 3.04X1X2+0.1100X12+0.6450X22 
The higher value of correlation coefficient for % CDR at 2nd hour 
signifies a good fit model. The coefficient of X1 and X2 was significantly 
lower and negative, indicating decrease in polymer concentration [X1= 
HPMCK100M (40-60 mg), X2=poly (styrene-divinylbenzene) (20-40 
mg)] could increase the percentage cumulative drug release at 2nd 
hour. Where else, a combination of X1X2 and individual squares of X21 
and X22 has agonistic effect with drug release, means drug release 
could get decrease with increase concentration of X1 and X2. But the 
coefficient values of X21, X22 and X1X2 was smaller, means has less 
influence on % CDR at 2nd Hour. (table 7 and 8). 
From the counterplot, it was confirmed that HPMC K100M; 50 mg and 
poly (styrene-divinylbenzene); 30 mg concentration provides good drug 
release profile (Coded value: 0, 0). That means VF5 formulation batch 
have proper dissolution profile. On the other hand, from 3D surface plot, 
it was assumed that decrease concentration of polymers could increase 
the percentage cumulative drug release in parallel manner. From the 
residual vs run model it was confirmed that except one, all the 
formulation retained between the limits of externally standard units. 
From predicted vs actual curve, it was confirmed that the statistical 
model maintained good linearity and design predicted %CDR at 2nd hour 
is almost coincide with actual %CDR at 2nd (fig. 2).  
Effect of polymers concentration on %CDR at 8th hour 
Using Design Expert® 11 software in vitro percentage cumulative 
drug release study was statistically interpreted at 8th hour. Based on 
ANOVA analysis, quadric model was selected. In the quadric model, 
F-value was 332.16, which implies the model was significant. There 
was only a 0.03% chance that an F-value this large could occur due 
to noise. Statistically, F value helps to indicate a group of variables 
are jointly significant or not. The F value of test is larger than F 
statistics, hence rejection of null hypothesis is palpable and 
accepting the alternative hypothesis was accepted. Nevertheless, P-
values less than 0.0500 indicate model terms were significant. In this 
case X1 X2, X1X2, X2² are significant model terms. Values greater than 
0.1000 indicate the model terms were not significant. 
The Predicted R² of 0.9859 is in reasonable agreement with the Adjusted 
R² of 0.9952; i.e. the difference is less than 0.2. Adequate Precision 
measures the signal to noise ratio. A ratio greater than 4 is desirable. In 
this experiment ratio was 57.338 indicates an adequate signal (table 
9and10). This model can be used to navigate the design space. 
Polynomial equation for % CDR at 8th Hour (Y2) =+84.05-4.58X1-
3.86X2 0.2400X1X2+0.4150X12+0.2100X22 
The moderate-higher value of correlation coefficient for % CDR at 8th 
hour signifies a good fit model. The coefficient of X1 and X2 was 
significantly lower and negative, indicating decrease in polymer 
concentration [X1= HPMCK100M (40-60 mg), X2= divinylbenzene) 
(20-40 mg)] could increase the percentage cumulative drug release 
at 8th hour. Where else, combination of X1X2 has shown negative sign 
with low coefficient value (0.2400), indicating increase in drug 
release profile. The individual squares of X21 and X22 have agonistic 
effect with drug release, means drug release could get decrease with 
increase concentration of X1 and X2. But the coefficient values of X21, 
X22 and X1X2 were smaller, means has less influence on % CDR at 8th 
Hour. From the counterplot, it was confirmed that HPMC K100M; 50 
mg and poly (styrene-divinylbenzene); 30 mg concentration 
provides good drug release profile (Coded value: 0, 0). that means 
VF5 formulation batch have proper dissolution profile after 8th hour 
of dissolution. On the other hand, from 3D surface plot, it was 
assumed that decrease concentration of polymers could increase 
percentage cumulative drug release in parallel manner. From the 
residual vs run model it was confirmed that except one, all the 
formulation retained between the limits of externally standard units. 
From predicted vs actual curve, it was confirmed that the statistical 
model maintained good linearity and design predicted %CDR at 8th 
hour was almost coinciding with actual %CDR at 8th hour (fig. 3). 
Probability plot 
With probability plot one can easily predict whether response 
variables follow a normal distribution or not. The response variables 
should coincide with the theoretical distribution and form 
approximately a straight line. Probability plot also helps to provide 
highest correlation coefficient. In this experiment, %CDR at 2nd and 
8th hour’s shows highest good correlations means drug releases with 
significance manner and maintain zero-order kinetics (fig. 4).  
Desirability function 
Desirability is a design function which ranged from zero to one. 
Among multiple function, numerically a point which is closer to one 
is more desirable. The overall desirability was found to be 0.927. 
From the 3D and counter desirability plot, it was confirmed that 
maximum desirability obtained at HPMC K100M (50 mg) and Poly 
(styrene-divinylbenzene) (30 mg) concentration (Coded value: 0, 
0)(fig. 5). 
Checkpoint analysis and optimization of batch 
From the optimization parameters and desirability study, it was 
anticipating that VF5 batches formulations could be the optimized 
one. To understand properly three checkpoint batches (VF10, VF11, 
and VF12) was prepared. The 2nd and 8th hours of %CDR was 
compared with predicted values of the overly plot. In overlay plot, 
yellow colour space indicates maximum possibility to produce 
desired formulation within this lining. The relative standard error 
must not exist 9%. This is very crucial part of Response Surface 
Methodology (RSM); as after studying the effect of independent 
variables on dependent variables or response variables, the 
optimum response was determined. It was observed that response 
variables of checkpoint batches were cognitive with VF5 
formulations (table 11), hence VF5 batch can be considered as 
optimized batch. However, drug kinetic study is needed to select 
best formulation with good controlled release property.  
Kinetic studies 
The kinetic study of drug dissolution profiles of all the formulations 
was prerequisite to find best-optimized formulation. However, from 
the Design Expert output, VF5 was selected as the best batch. But, 
without kinetic study one cannot predict the actual reality of drug 
release pattern. In this study, the drug release profile with time was 
fitted with various models. The criteria for selecting best fitting model 
were, the regression coefficient (R2), which must be near to one. 
Similarly, AIC, BIC, K1, RMSE, Dissolution Efficiency (DE) must be in 
lest number in best selected model as compare to other models. As far 
as Mean Dissolution Time (MDT) was concerned, which indicates 50% 
of drug release from the formulation, can helps to characterize the 
retarding rate of polymers and drug-releasing ability. A higher MDT 
value indicates a higher drug retarding ability of polymers. The 
formulation VF5 has shown highest MTD value (5.19) as compare to 
other formulations, indicating 50 mg of HPMC K100M and 30 mg of 
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poly (styrene-divinylbenzene) has good drug retarding ability, where 
else VF2 with 50 mg HPMC K100M and 0 mg poly (styrene-
divinylbenzene) shows lest MDT value of 3.431, indicating poor 
polymeric retention of drug with higher drug release. The Percentage 
Dissolution Efficacy (DE) was also found to be moderately high 
(56.39%). Similarly, Bayesian Information Criterion (BIC) or Schwarz 
Criterion and Akaike information criterion (AIC) also helps to find best 
model among finest set of models; the model with the lowest BIC and 
AIC values was preferred as best model. AIC helps to find best quality 
and goodness of fit model. Within all formulations once again, VF5 has 
lowest AIC (54.97) and BIC (55.13) value. On the contrary, VF5 follow 
zero-order kinetics as R2 value (0.9396) was maximum as compared to 
First order, peppas, hixon crowell, higuchi model of VF5 formulation. 
Hence statistically it can be postulating that VF5 could be the best 
formulation with good diffusion-controlled released system (fig. 6 and 
table 12).  
Stability study 
The accelerated stability study of VF5; an optimized formulation was 
carried out as per ICH Q1A guideline at 40 °C±2 °C/75% RH±5% RH for 
6 mo using EZT-570S touch screen stability controller. Various physical 
parameters like hardness, friability, floating time, percentage drug 
content, %CDR at 12th hour was measured. After 6-month stability study 
VF5 formulations shows no significant changes in instability. However, 
floating time and % cumulative drug release was significantly increasing 
during stability study, it may be due to the slight deformation of API 
during stability study (table 13) To know more about actual interaction 
or changes during 6 mo of stability study, two-way ANOVA was 
implicated. It shows interaction account for 0.12% of total variables. The 
F value was 16.30, the degree of freedom number was 4. The P-value 
was<0. 0001. As per two-way ANOVA the interaction was considered 
extremely significant and interaction was statistically significant. 
 
 
Fig. 1: % CDR profile of valsartan floating tablets (VF1-VF9 batches) at 95.00% CI of differences and at mean±SD (n=3); **** indicates high 
statistically significance (p<0.005) 
 
 
Fig. 2: Design expert output [A-counter, B-3D surface plot, C-residual vs run plot D-actual vs predicted plot] of effect of polymers 
concentration on % CDR at 2nd h 
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Fig. 3: Design expert output [A-counter, B-3D surface plot, C-residual vs run Plot D-actual vs predicted plot] of effect of polymers 
concentration on % CDR at 8th h 
 
 
Fig. 4: Comparative probability plot of % CDR at 2nd and 8th h 
 
Table 1: Selection of variables levels for independent variables 
(Independent variables) 
Levels  
 
Coded value Concentration of HPMC K100M in mg (X1) Concentration of poly (Styrene-divinylbenzene) 
in mg (X2) 
Low -1 40 20 
Intermediate  0 50 30 
High  +1 60 40 
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Fig. 5: Desirability function [A-bar chart, B-ramps chart, C-3D surface plot chart, D-counter plot] 
 
 
Fig. 6: [A]. Comparative mean dissolution study for VF1 to VF9 formulation at 95.00%, CI of differences, and at mean±SD (n=3) [B]. A 
comparative profile of AIC and BIC values are represented as mean±SD (n=3) on various valsartan floating formulations AIC and BIC at 
95.00% CI of differences, ** indicates high statistically significance (p<0.005) 
 
Table 2: Composition of factorial design batch 
Ingredients (mg) VF1 VF2 VF3 VF4 VF5 VF6 VF7 VF8 VF9 
Valsartan 160 160 160 160 160 160 160 160 160 
HPMC K100 M 40 50 60 40 50 60 40 50 60 
Poly (styrene-divinylbenzene) 20 20 20 30 30 30 40 40 40 
DCP 55 45 35 45 35 25 35 25 15 
Sodium bi carbonate 20 20 20 20 20 20 20 20 20 
Magnesium stearate 3 3 3 3 3 3 3 3 3 
Talc 2 2 2 2 2 2 2 2 2 
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Table 3: Pre compression parameters for all the factorial batches 
Batch 
number 
Angle of 
repose ( °) 
Bulk density 
(g/ml) 
Tapped 
density(g/ml) 
Carr’s compressibility 
index (%) 
Hausner 
ratio 
Total porosity 
(%) 
Drug content 
(%) 
VF1 32.87±0.012 0.234±0.128 0.263±0.129 11.02±0.013 1.12±0.014 11.02±0.031 92.12±0.056 
VF2 33.28±0.023 0.220±0.023 0.254±0.023 13.38±0.121 1.15±0.123 13.38±0.023 93.17±0.034 
VF3 35.18±0.123 0.230±0.213 0.267±0.271 13.85±0.025 1.16±0.014 13.85±0.128 94.18±0.112 
VF4 34.29±0.283 0.241±0.128 0.277±0.361 12.99±0.013 1.14±0.022 12.99±0.313 97.19±0.312 
VF5 37.29±0.281 0.217±0.278 0.250±0.273 13.20±0.028 1.15±0.015 13.20±0.122 93.22±0.023 
VF6 31.28±0.023 0.234±0.023 0.263±0.172 12.35±0.312 1.12±0.014 11.02±0.028 96.29±0.003 
VF7 29.38±0.381 0.245±0.112 0.267±0.281 8.239±0.024 1.08±0.341 8.239±0.112 98.18±0.912 
VF8 33.56±0.824 0.223±0.238 0.288±0.271 19.09±0.012 1.29±0.023 22.56±0.091 94.18±0.923 
VF9 38.39±0.213 0.234±0.123 0.254±0.234 7.967±0.023 1.08±0.044 7.874±0.912 95.29±0.021 
All results were shown in mean±SD (n=3) 
 
Table 4: List of variable importance for precompression parameters 
Pre compression variables  Variable number Power Importance 
Total porosity (%) 7 0.996230 1 
Hausner ratio 6 0.991326 2 
Carr’s compressibility index (%) 5 0.965853 3 
Tapped density(g/ml) 4 0.916766 4 
Bulk density (g/ml) 3 0.905470 5 
Drug content (%) 8 0.754903 6 
Angle of repose( °) 2 0.535868 7 
 
Table 5: Post compression parameters for all the formulations 
Batch 
number  
Average 
weight (mg)  
Weight variation 
test (%) 
Drug content 
(%)  
Hardness 
(kg/cm2) 
Thickness 
(mm)  
Friability 
(%)  
Floating  
Time (sec) 
In vitro buoyancy 
study (h) 
VF1 300.51 ±0.050(Pass) 92.34±0.45 5.6±0.02 5.4±0.18 0.412±0.28 116±0.37 14 
VF2 298.23 ±0.809(Pass) 96.23±0.36 5.2±0.06 5.2±0.27 0.429±1.61 123±0.14 15 
VF3 302.21 ±0.514(Pass) 97.38±0.11 5.7±0.13 5.6±0.37 0.491±0.82 136±0.02 18 
VF4 301.20 ±0.178(Pass) 96.68±0.87 5.2±0.22 5.5±0.33 0.512±1.27 127±0.22 >24 
VF5 302.17 ±0.005(Pass) 98.11±0.38 4.8±0.51 5.7±0.38 0.613±0.22 132±0.33 18 
VF6 300.47 ±0.064(Pass) 99.13±1.45 5.2±0.02 5.1±0.15 0.531±0.38 123±0.16 >24 
VF7 301.63 ±0.321(Pass) 96.19±0.41 5.9±0.22 5.8±1.82 0.556±0.08 117±0.05 17 
VF8 300.28 ±0.127(Pass) 98.29±0.62 6.4±0.27 5.4±0.22 0.536±0.28 125±0.18 16 
VF9 299.27 ±0.463(Pass) 96.31±0.42 5.7±0.28 5.3±0.02 0.572±0.31 130±0.37 >24 
All results were shown in mean±SD (n=3) 
 
Table 6: variables importance for post compression parameters 
Post compression variables  Variable number Power Importance 
Thickness (mm) 4 0.923526 1 
Average weight (mg) 1 0.832101 2 
Drug content (%) 3 0.776889 3 
Friability (%) 2 0.693686 4 
Floating time (see) 5 0.620322 5 
Hardness (kg/cm2) 6 0.172067 6 
 
Table 7: Level of significance of R2 value 
Std. Dev. 0.2560 R² 0.9995 
Mean 28.89 Adjusted R² 0.9987 
C. V. % 0.8858 Predicted R² 0.9944 
  Adeq Precision 102.6078 
 
Table 8: ANOVA for quadratic model on %CDR at 2nd h 
Source Sum of squares df Mean square F-value p-value  
Model 393.65 5 78.73 1201.78 <0.0001 significant 
X1-HPMC K100 M 239.40 1 239.40 3654.37 <0.0001  
X2-poly (styrene divinylbenzene) 116.42 1 116.42 1777.17 <0.0001  
X1X2 36.97 1 36.97 564.28 0.0002  
X1² 0.0242 1 0.0242 0.3694 0.5863  
X2² 0.8321 1 0.8321 12.70 0.0377  
Residual 0.1965 3 0.0655    
Core Total 393.85 8     
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Table 9: Fit statistics for % CDR at 8th h 
Std. Dev. 0.3608 R² 0.9982 
Mean 84.47 Adjusted R² 0.9952 
C. V. % 0.4271 Predicted R² 0.9859 
  Adeq Precision 57.3382 
 
Table 10: ANOVA for quadratic model at 2nd h of %CDR 
Source  Sum of square  Df Mean square  F-value  P-value   
Model 216.17 5 43.23 332.16 0.0003 significant 
A-HPMC K100 M 125.95 1 125.95 967.69 <0.0001  
B-poly (styrene-divinylbenzene) 89.55 1 89.55 688.04 0.0001  
AB 0.2304 1 0.2304 1.77 0.2755  
A² 0.3444 1 0.3444 2.65 0.2023  
B² 0.0882 1 0.0882 0.6777 0.4707  
Residual 0.3905 3 0.1302    
Cor Total 216.56 8     
 
Table 11: Checkpoint batch and standard error: 
 Actual Predicted Standard error 
Checkpoint Batch %CDR at 2nd 
Hour 
%CDR at 8th 
Hour 
%CDR at 2nd 
Hour 
%CDR at 8th 
Hour 
for %CDR at 2nd 
Hour 
For % CDR at 8th 
Hour 
VF10 29.67 87.48 28.39 84.05 4.31 3.92 
VF11 30.29 85.28 28.39 84.05 6.27 1.44 
VF12 29.36 86.67 28.39 84.05 3.30 3.02 
 
Table 12: Comparative kinetic model for VF1 to VF9 batches 
Statistical analytical criteria VF1 VF2 VF3 VF4 VF5 VF6 VF7 VF8 VF9 
Zero 0.8726 0.918 0.911 0.9162 0.9396 0.8949 0.878 0.85948 0.8899 
First  0.9841 0.7801 0.8465 0.8809 0.7307 0.8994 0.9657 0.9529 0.9604 
Peppas 0.8099 0.8253 0.8308 0.8256 0.8683 0.82 0.8357 0.8452 0.8427 
Hixon Crowell 0.8573 0.8904 0.8831 0.8857 0.9198 0.8675 0.8767 0.8732 0.8765 
Higuchi 0.9586 0.9523 0.961 0.961 0.9328 0.9669 0.9598 0.9502 0.9532 
AIC (Akaike Information Criterion) 61.555 57.27 85.324 84.905 54.97 85.803 86.35 86.37 141.62 
BIC (Bayesian Information Criterion or 
Schwarz Criterion) 
61.714 5.74E+
01 
85.483 85.064 55.13 85.961 85.51 86.53 141.78 
K1 0.34 0.332 0 0.28 0.324 0 0 0 0.313 
RMSE (Root Mean Squared Error) 12.9037 98.73 56.99 55.527 8.55 58.731 60.802 60.877 1923.25 
Percentage Dissolution Efficiency 
(DE)(%) 
70.1512 70.15 64.19 62.23 56.39 67.104 69 68.705 66.58 
Mean Dissolution Time (MDT)(hr) 3.439 3.431 4.3056 4.377 5.19 3.947 3.71 3.75 3.861 
 
Table 13: Accelerated stability study of VF5 formulation batch as per ICH Q1A guideline 
Duration  Hardness (Kg/cm2)  Friability (%) Floating time (See) %Drug content  %CDR at 12th hours  
Initial 4.8±0.43 0.613±0.22 132±0.33 98.11±0.38 99.38±0.51 
1st month  4.4±1.51 0.602±0.51 133±0.45 98.10±0.11 100.23±0.67 
2nd month  4.1±0.23 0.588±0.71 134±0.13 97.76±0.30 101.34±1.51 
3rd month  3.8±0.32 0.561±0.29 137±0.18 97.51±0.34 102.45±1.34 
4th month  3.7±0.41 0.551±0.31 139±0.43 97.21±0.58 104.24±1.05 
5th month  3.6±0.46 0.543±0.72 141±0.11 96.13±0.18 104.34±1.22 
6th month  3.5±0.27 0.531±0.11 144±0.34 95.11±0.22 105.35±2.14 
All results were shown in mean±SD (n=3) 
 
Table 14: Two-way ANOVA results for stability study for VF5 formulation batch as per ICH Q1A guideline 
Source of variation % of total variation P value P value summary Significant?  
Interaction 0.1167 <0.0001 **** Yes  
Row factor 0.02947 <0.0001 **** Yes  
Column factor 99.79 <0.0001 **** Yes  
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 885.8 24 36.91 F (24, 210) = 16.3 P<0.0001 
Row factor 223.7 6 37.29 F (6, 210) = 16.47 P<0.0001 
Column Factor 757655 4 189414 F (4, 210) = 83649 P<0.0001 
Residual 475.5 210 2.264   
**** indicates a higher level of significance 
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DISCUSSION 
The main intention of this research was to evaluate valsartan 
floating tablets using various statistical approach. To prepare 160 
mg valsartan to contain floating tablets, 40-60 mg of HPMC K100 M 
and 20-40 mg of poly (styrene-divinylbenzene) were used as 
principal polymers as shown in table 2. From the precompression 
parameters of all the nine factorial batches shown in table 3, it was 
confirmed that all the formulation bland has fair to good angle of 
repose (29.38±0.381 to 38.39±0.213⁰), excellent bulk density 
(0.217±0.278 to 0.245±0.112 g/ml), excellent tapped density 
(0.250±0.273 to 0.288±0.271 g/ml), good percentage carr’s 
compressibility index (7.967±0.023 to 19.09±0.012 %), moderate 
hausner ratio (1.08±0.044 to1.16±0.014), good percentage porosity 
(7.874±0.912 to 22.56±0.091 %) and adequate percentage drug 
content (92.12±0.056 to 98.18±0.912 %). From the variable 
importance studies performed in Statistica 12 software on post 
compression parameters mentioned in table 4, it was confirmed 
that, among the pre-compression parameters, total porosity (%) has 
highest variable importance, hence total porosity (%) could 
influence valsartan floating tablet efficacy. In a similar pattern, from 
post-compression parameters, all the batches reported to have very 
good tablet average weight (298.23 to 302.21 mg), limited 
percentage weight variation, excellent percentage drug content 
(92.34±0.45 to 99.13±1.45 %), adequate hardness (4.8±0.51 to 
6.4±0.27 kg/cm2), moderate thickness (5.1±0.15 to 5.8±1.82 mm), 
limited percentage friability (0.412±0.28 to 0.613±0.22 %) and 
effective floating time (116±0.37 to 136±0.02 see). From the 
statistical variable importance study performed in Statistica 12 
software (table 6) on post-compression parameters, it was 
confirmed that tablet thickness has higher influence on floating 
tablets of valsartan. From the comparative kinetic model studies 
shown in table 12 on all the nine batches, it was proposed that VF5 
happened to be the optimized formulation because it follows best 
zero-order kinetics (R2=0.9396), minimum AIC value (54.97) and 
minimum BIC (55.13) value as compared with the rest of the 
formulations. Nevertheless, VF5 reported to have marginal RMSE 
value (8.55) and least Percentage Dissolution Efficacy (PDE) 
(56.39%) and higher Mean Dissolution Time (MDT) (5.19hr) as 
compared to other formulations. Further, by performing desirability 
study it was confirmed that VF5 was found to be the best-optimized 
batch. The optimized VF5 formulation was observed in accelerated 
stability condition as per ICH Q1A guideline; and found to have very 
stable after six-month stability studies.  
CONCLUSION 
Valsartan floating drug delivery system was developed by 
considering HPMC K100M and poly (styrene-divinylbenzene) as 
principal polymers. Total nine formulations were prepared (VF1-
VF9) and optimized by Response Surface Mythology (RSM) based 
Box-Bentham design. The main intention of this research was to 
evaluate valsartan floating tablets using various statistical approach. 
After all the evaluation studies VF5 formulations was emerges as an 
optimized formulation. From the six-month stability study results of 
VF5 formulations, it was also reviled that the VF5 formulation; 
encompassing 50 mg of HPMC K100M and 30 mg poly (styrene-
divinylbenzene) shows no significant changes in physical and 
chemical characteristics after six months accelerated conditions (40 
°C±2 °C/75% RH±5% RH). Thus, from the above conclusion, it was 
summarized that valsartan floating tablets were successfully 
prepared but in vivo bouncy study and in vivo pharmacokinetics in 
an animal model is warrant to established proper in vitro and in vivo 
correlation.   
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